Our Pricing

Wegovy UK Price Comparison: Save with Code WEIGHTLOSSNEW

Looking for a comprehensive wegovy uk price comparison to find the best value for your weight loss treatment? At Cured Pharmacy, Wegovy starts from £79.00 with our discount code WEIGHTLOSSNEW, offering transparent upfront pricing, UK-registered prescribers, and discreet next-day delivery across the United Kingdom.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity [1]. Semaglutide mimics a natural hormone that regulates appetite and food intake, helping you feel fuller for longer and reducing calorie consumption throughout the day.

In the landmark STEP 1 clinical trial, participants using Wegovy achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. This substantial difference demonstrates the clinical efficacy of semaglutide when combined with lifestyle modifications including a reduced-calorie diet and increased physical activity.

Wegovy is administered as a once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm. Treatment begins with a lower dose that gradually increases over 16-20 weeks to minimise gastrointestinal side effects, reaching a maintenance dose of 2.4 mg weekly [2]. All dosing schedules must be determined by a UK prescriber following clinical assessment.

Wegovy UK Price Comparison Across Online Pharmacies

Wegovy pricing varies significantly across UK online pharmacies, making price comparison essential for patients managing long-term treatment costs. At Cured Pharmacy, our transparent pricing model shows exact costs before you complete your clinical consultation, with Wegovy available from £79.00 when you use discount code WEIGHTLOSSNEW.

Many UK pharmacies advertise competitive rates but add hidden consultation fees, delivery charges, or subscription requirements that inflate the final cost. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures all pricing remains transparent, with no surprise fees or mandatory subscription models that lock you into long-term commitments.

The cost of Wegovy typically reflects the dose prescribed by your clinician. Treatment usually begins with the 0.25 mg starter dose, progressing through 0.5 mg, 1 mg, and 1.7 mg before reaching the 2.4 mg maintenance dose. Your UK prescriber will determine the appropriate dose escalation schedule based on your response to treatment and tolerability.

Understanding Wegovy Pricing Structure

Wegovy pens are supplied in pre-filled, single-use injection devices containing four doses per pack. The price per pack depends on the prescribed strength, with lower starter doses generally costing less than higher maintenance doses. At Cured Pharmacy, we guarantee the lowest UK prices across all dose strengths, with upfront pricing displayed before your consultation begins.

How to Use Discount Code WEIGHTLOSSNEW

Cured Pharmacy offers £79.00 off your first Wegovy order when you apply discount code WEIGHTLOSSNEW at checkout. This discount applies automatically to eligible weight loss treatments, reducing your initial treatment cost and making long-term weight management more affordable from the start.

To redeem your discount, complete the free online consultation with our UK-registered clinical team, which takes under three minutes. Once your prescription is approved by a UK prescriber, proceed to checkout and enter code WEIGHTLOSSNEW in the discount field before completing payment. The £79.00 reduction will be applied immediately to your order total.

Our discount codes are designed to support patients beginning their weight loss journey, recognising that sustained treatment requires both clinical effectiveness and financial accessibility. Unlike subscription-based models that require ongoing commitments, our discount applies to individual orders, giving you complete flexibility in managing your treatment schedule.

Wegovy vs Alternative Weight Loss Treatments

Several prescription weight loss treatments are licensed in the UK, each working through different mechanisms. While Wegovy (semaglutide) is a once-weekly GLP-1 receptor agonist, other options include dual GIP/GLP-1 receptor agonists and lipase inhibitors, each with distinct clinical profiles and pricing structures.

Clinical trial data shows varying efficacy across different treatments. The STEP trials demonstrated that semaglutide 2.4 mg produced greater weight loss than liraglutide 3 mg, with participants losing an average of 14.9% body weight compared to 8% with liraglutide over similar timeframes [1][3]. Newer dual-pathway medications have shown even higher efficacy in head-to-head comparisons, though individual response varies significantly.

Your UK prescriber will consider multiple factors when recommending treatment, including your BMI, medical history, previous weight loss attempts, contraindications, and personal preferences regarding injection frequency. Some patients prefer daily injections for consistent routine, while others find once-weekly administration more convenient for long-term adherence.

Choosing Between Injectable and Oral Treatments

Injectable GLP-1 treatments like Wegovy typically produce greater weight loss than oral alternatives such as orlistat, which works by blocking fat absorption in the digestive system [4]. However, oral medications may be preferred by patients uncomfortable with self-injection or those with milder weight management needs. Your prescriber will discuss all suitable options during your clinical assessment.

What to Expect During Wegovy Treatment

Wegovy treatment follows a structured dose escalation schedule designed to minimise gastrointestinal side effects while optimising weight loss outcomes. Most patients begin with 0.25 mg weekly for four weeks, then increase to 0.5 mg for four weeks, followed by monthly increases to 1 mg, 1.7 mg, and finally 2.4 mg maintenance dose [2].

Common side effects include nausea, diarrhoea, vomiting, constipation, and abdominal pain, which typically decrease as your body adjusts to each dose level [2]. These effects are generally mild to moderate and resolve within a few weeks. If side effects persist or become severe, your prescriber may recommend staying at your current dose longer before escalating, or adjusting your treatment plan.

Clinical trials showed that most weight loss occurs during the first 60 weeks of treatment, with participants continuing to lose weight throughout the dose escalation phase and into maintenance therapy [1]. Weight loss should be combined with lifestyle modifications including a reduced-calorie diet and increased physical activity for optimal results. Regular follow-up with your healthcare provider ensures treatment remains safe and effective throughout your weight loss journey.

Monitoring Your Progress

Your UK prescriber will recommend regular weight monitoring and periodic clinical reviews to assess treatment response. NICE guidelines suggest that if you haven't achieved at least 5% weight loss after 12 weeks on the maintenance dose, alternative treatment options should be considered [5]. Cured Pharmacy's clinical team provides ongoing support throughout your treatment, with easy access to prescriber consultations when you have questions or concerns.

Is Wegovy Right for You? Clinical Eligibility

Wegovy is licensed in the UK for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [1]. Your UK prescriber will calculate your BMI during the online consultation and review your medical history to determine clinical suitability.

Certain medical conditions and medications may contraindicate Wegovy use. The treatment is not suitable for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [2]. Your prescriber will also review current medications for potential interactions, particularly if you take insulin or sulfonylureas, which may require dose adjustments to prevent hypoglycaemia.

Wegovy is not recommended during pregnancy or breastfeeding, and women of childbearing potential should use effective contraception during treatment [2]. If you're planning pregnancy, your prescriber will discuss discontinuing Wegovy at least two months before conception. All prescription medications dispensed by Cured Pharmacy require clinical assessment by a UK-registered prescriber, ensuring treatment is both safe and appropriate for your individual circumstances.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Retrieved from https://www.medicines.org.uk/emc/product/13799
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., & Wilding, J. P. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
4. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155
5. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. Retrieved from https://www.nice.org.uk/guidance/ta875
6. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.